Bimekizumab: 14 agencies, 2021–2026
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
PBAC (Australia) has been easier on bimekizumab than on its own caseload: it refused 0 of 7 decisive submissions here (0%), against a base rate of 24% across everything it has assessed.
Assessment has run over 5.2 years, from 13 Jul 2021 at AWMSG (Wales) to 20 Sep 2026 at NYE METODER (Norway).
AOTMIT (Poland) changed its position: not recommended on 13 Sep 2022, restricted by 16 Jul 2025, after a resubmission.
No assessment is on file from PHARMAC (New Zealand), which is among the eight highest-volume agencies here.
Not every gap is a refusal: for bimekizumab, 2 were withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 42 of 55 records date from 2023 or later.
The programme is broad: 16 distinct indication wordings are recorded for bimekizumab by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
8 of these 55 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess bimekizumab, on 13 Jul 2021; HIRA (South Korea) did not open a file until 6 Feb 2025 — a wide spread of 3.6 years between the earliest and latest system to look at it.
The record arrives in waves: 5 separate years each carry two or more decisions, spread across 6 years in total.
Restriction is doing real work here: 11 of 44 decisive outcomes narrowed bimekizumab to a subgroup rather than accepting or refusing it outright, at AOTMIT (Poland), HIRA (South Korea) and NICE (England) among others.
11 of the 14 agencies here assessed bimekizumab more than once, PBAC (Australia) most often at 8 entries — repeat review is the norm for this molecule rather than the exception.
bimekizumab has been through 14 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for bimekizumab reads 28 recommended, 11 restricted, 5 not recommended and 4 no benefit, with 7 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| AOTMIT (Poland) | 16 Jul 2025 | programu lekowego B.161: „Leczenie chorych z ropnym zapaleniem apokrynowych gruczołów potowych (HS) (ICD-10: L 73.2) | recommended conditionally | source |
| PBAC (Australia) | 2025 | Hidradenitis suppurativa (HS) | Recommended | source |
| SMC (Scotland) | 7 Apr 2025 | For the treatment of active moderate to severe hidradenitis suppurativa (HS) in adults with an inadequate response to conventional systemic HS therapy. | accepted (restricted) | source |
| HIRA (South Korea) | 6 Feb 2025 | 판상 건선 | reimbursable only at the evaluated price | source |
| DMC (Denmark) | 13 Dec 2023 | Non-radiografisk aksial spondylartrit (nr-axSpA) og ankyloserende spondylitis (AS) | Ikke anbefalet | source |
50 further decisions for bimekizumab, across 13 agencies, are not shown here. They include the most recent record on file, 20 Sep 2026 from NYE METODER (Norway); its outcome is in the subscriber dataset. They link to 36 further source documents.
Related molecules
- adalimumab — same ATC class L04A — Immunosuppressants
- upadacitinib — same ATC class L04A — Immunosuppressants
- secukinumab — same ATC class L04A — Immunosuppressants
- tocilizumab — same ATC class L04A — Immunosuppressants
- ustekinumab — same ATC class L04A — Immunosuppressants
- infliximab — same ATC class L04A — Immunosuppressants
Coverage: 55 decisions for bimekizumab from 14 agencies, 2021 to 2026. Data to 7 Sep 2026. ATC class L04A — Immunosuppressants. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.